LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Jan 7, 2022
Distillery Therapeutics
NRP1 inhibition for bone marrow regeneration
Read More
BioCentury
|
Nov 6, 2020
Targets & Mechanisms
Data Byte: newly identified host factors that regulate ACE2 expression
Several recent publications highlighting host factors that modulate ACE2 expression point to possible new targets for COVID-19 therapies. ACE2 and TMPRSS2 are the most common host targets
Read More
BioCentury
|
Dec 21, 2018
Company News
Astellas exercises option to acquire Potenza
Read More
BioCentury
|
Nov 26, 2018
Distillery Techniques
Drug delivery
Read More
BioCentury
|
Aug 9, 2018
Preclinical News
New biological insight could lead to obesity treatment
Read More
BioCentury
|
Dec 5, 2017
Distillery Therapeutics
Cancer
Read More
BioCentury
|
Jan 12, 2017
Emerging Company Profile
Looking beyond VEGF
How SemaThera targets vascular pathologies in the retina where anti-VEGF fails
Read More
BioCentury
|
Nov 12, 2015
Distillery Therapeutics
Therapeutics: Vascular endothelial growth factor receptor 1 (FLT1; VEGFR-1); neuropilin 1 (NRP1)
Read More
BioCentury
|
Mar 30, 2015
Clinical News
Tivozanib: Phase II final data
Read More
BioCentury
|
Jul 17, 2014
Distillery Therapeutics
Indication: Ophthalmic disease
Read More
Items per page:
10
1 - 10 of 27